Response to Biancheri et al. and Boepsflug-Tanguy et al.: AIMP1/p43 Connatal PMLD  by Feinstein, Miora et al.
in such early-onset forms of neurodegenerative diseases.7
In this respect, it would have been interesting if the
authors had provided neurophysiological analyses, partic-
ularly on the peripheral nerve functions of their patients.
The clinical and MRI presentation of the AIMP1mutated
patients reported in this paper is in agreement with the
important role of AIMP1 in regulating neurofilament and
maintaining axon-cytoskeleton integrity, and not as a
primitive disorder of the myelination. Nevertheless, in
such a highly inbred population, we cannot rule out the
possibility of another mutated gene implicated in the
etiology of the complex phenotype.8
In conclusion, the genetician and neurologist cannot
consider AIMP1 as a candidate gene for PMLD mutations.
Patients with early severe neurodegenerative disorder
involving axonal functions and myelin development seem
presently more appropriate for AIMP1mutation screening.
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AIMP1/p43 Connatal PMLDTo the Editor: We have recently described a severe neuro-
logical phenotype with rapid progression over the first
months of life that is caused by a homozygous mutation
in AIMP1/p43.1 The study was approved by the Soroka
Medical Center Institutional Review Board. All patients
had severe failure to thrive with a concordant head circum-ference (not isolated microcephaly), severe global develop-
mental delay, and coarse face, yet no significant dysmor-
phism. Although the phenotype differs at some points
from the classical form of Pelizaeus-Merzbacher disease
(PMD), as suggested by Biancheri et al. and Boespflug-
Tanguy et al. in this issue of The Journal, it is extremely
similar to that of the severe (connatal) form of the
disease.2–4 The main features of the PMD clinical pheno-
type were apparent in our patients:1 nystagmus, hypotonia
with progressive spastic parapersis, and developmental
delay. Furthermore, dysarthria, wasting (dystrophy) of
the limbs, and kyphoscoliosis, found in our patients,can Journal of Human Genetics 88, 391–395, March 11, 2011 393
Figure 1. Magnetic Resonance Imaging of AIMP1/p43 Homozy-
gous Patient, Age 4 Years
T1 white matter signal is hypointense relative to gray matter
signal.have all been previously well documented in connatal
PMD with proven PLP1 mutations.2 Seizures, which are
not common in PMD yet which do appear in severe cases
of connatal PMD,2–4 were seen in only two of the seven
patients and only on rare occasions in those two. The
course of disease progression was more rapid than in the
classical milder form of PMD. However, the PMD pheno-
type has a significant scope of severity,5 with our patients
fitting well into themore severe connatal PMD phenotype,
which entails early progression.2–4 It is also noteworthy
that mouse experiments show dramatic variation in PMD
phenotype severity and progression dependent on various
genetic backgrounds.5 Moreover, in Hsp60 mutations,
designated as hypomyelinating leukodystrophy type 4
(HLD4 [MIM 612233]), early progression and seizures
appear in the majority of patients.6
Thus, there is no doubt that the AIMP1/p43mutation we
described1 causes a severe neurological phenotype with
clinical features extremely similar to the more severe con-
natal PMD phenotype and to that of HLD4, and there is no
doubt that in terms of pure clinical phenotype, the disease
is indeed connatal PMD-like, as we claimed in the
December 2010 issue of The Journal.1 There is also no
controversy as to the relative paucity of myelin in the
brains of affected individuals. Regarding disease mecha-
nism and MRI: in Feinstein et al.,1 Figure 2D (FLAIR) was
labeled erroneously as T1. The correct T1 image given
here (Figure 1) demonstrates hypointensity of white
matter, alleviating much of the concerns raised by Bian-
cheri et al. and Boespflug-Tanguy et al. In fact, careful
review of all available magnetic resonance images (MRIs)
of affected individuals in that kindred demonstrated
similar findings (data available upon request). There is
very significant variation in the MRI data in documented
PMD cases,7 and the findings in our patients are well
within that wide spectrum. Interestingly, brainstem audi-
tory-evoked potentials (waves III, IV, and V) generated in
the pons are absent in patients with PMD.8 However,
hyperintense MRI signals in the pons (not found in our
patients), although documented in Pelizaeus-Merzbacher-
like disease (PMLD), are rarely found (if at all) in PMD.9
The existing MRI data are thus well within the scope of
a PMD-like phenotype. This is not to say that they are suffi-
cient for clear determination of whether the disease is due
to demyelination secondary to neurodegeneration rather
than primary hypomyelination. As is well suggested and
discussed in our manuscript,1 and as emerges from
new MRI guidelines in determining hypomyelination,9
the connatal PMD-like clinical phenotype in this disease
more likely emerges because of a neurodegenerative
process of impaired myelin formation and/or preservation
secondary to aberrant AIMP1-dependent maintenance of
neurofilament integrity. This is well in line with detailed
proton magnetic resonance spectroscopy studies done in
three pure PMD cases demonstrating in the white matter
of all cases diffuse or focal reductions in N-acetylaspartate
that seemed to be consistent with axonal damage.10 Thus,394 The American Journal of Human Genetics 88, 391–395, March 1PMD and several of the PMLDs, classically defined as hypo-
myelinating disorders, likely arise in part from demyelin-
ation. In other words, as in many revelations emerging
through novel imaging technologies and molecular-
genetic analysis of long-recognized diseases, clinical classi-
fications and nomenclatures turn out to be not as clear cut
as previously thought. Further sequential MRI studies, as
well as neurophysiological analysis of peripheral nerve
function, are in place to determine whether the main
AIMP1/p43-related disease process is of demyelination
secondary to neurodegeneration or, less likely, of hypo-
myelination, if defined as a primary defect in myelin
formation and/or metabolism.
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